Chile’s Ministry of Science recognizes Cells for Cells as a success case in a white paper studying the factors that differentiate thriving university-derived businesses from less prosperous ones. The document…
Read More
Cells for Cells ('C4C'), a clinical-stage biotech pioneering allogeneic stem cell and stem-cells-derived therapeutics for high-impact chronic diseases, announced a 6-month follow-up of the groundbreaking Clinical Data from the First-ever...
Read More
After two years of the COVID-19 pandemic, scientists from different parts of the world met again at the annual meetings of the International Society for Cell Therapy (ISCT), and the…
Cells for Cells participated in the Startups Latam 2022 report launch as a leader and representative of the regenerative medicine industry in Latin America. The report and the launch event…
Cells for Cells (C4C), a pioneer in regenerative medicine biotech based in Chile, secured US$ 5.2 million from its historical investors to open a US-based holding company and a spin-off….
Cells for Cells and Universidad de los Andes were awarded the Fourth National Basal Funding Competition for Scientific and Technological Centers of Excellence, granted by the National Agency for Research…
Cells for Cells (C4C), a pioneering regenerative medicine company based in Santiago, Chile, received news of the obtention of a new CORFO grant that will support the advancement of its...
Read More
Every year, the Avonni Prize, the Chilean National Innovation Prize and “the most important honorary recognition in Chile,” awards the most promising technologies and solutions in an effort to make…
Recent Posts
- ISCT highlights observations from major Chilean advanced therapy developer group on Latin American regulation for Regenerative Medicine products in its recent Telegraft issue
- Chile’s Ministry of Science recognizes Cells for Cells as university spin-off success case in white paper
- Cells for Cells treats the first-ever patient with an exosome-produced therapy for osteoarthritis
- Cells for Cells presented groundbreaking results of three extracellular vesicles products at ISCT and ISEV annual meetings
- Cells for Cells featured in Startups Latam’s 2022 report
